The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD)

Publications

Abdullah HM, Narayana Gowda S, Sharma R, Ellithi M, Oberoi M

Temozolomide-Associated Organizing Pneumonia.

American journal of therapeutics 2022 Nov-Dec 01;29;e781-e783 — 2022 Nov-Dec 01 — e781-e783

Koschel D, Handzhiev S, Leucht V, Holotiuk O, Fisseler-Eckhoff A, Höffken G

Hypersensitivity pneumonitis associated with the use of temozolomide.

The European respiratory journal 2009 Apr;33;931-4 — 2009 Apr — 931-4

Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG

A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.

Journal of neuro-oncology 2001 Jul;53;259-65 — 2001 Jul — 259-65